CAP

The Port Authority of New York and New Jersey selects Locus Technologies Cloud Software for GHG Management

Retrieved on: 
Tuesday, April 9, 2024
Diamond, Software as a service, Waste management, Biophysical environment, GHG, ESG, Software, CAP, Locus Technologies, Record, Carbon, Ship, Sustainability, Port authority, Aircraft, EHS, Environmental Health (journal), Renewable energy

The expansion will include a comprehensive application to capture operational and organizational greenhouse gas (GHG) and criteria air pollutant (CAP) emission inventories from all Port Authority activities.

Key Points: 
  • The expansion will include a comprehensive application to capture operational and organizational greenhouse gas (GHG) and criteria air pollutant (CAP) emission inventories from all Port Authority activities.
  • This application will expand the Port Authority’s current Locus applications for construction sustainability and waste management.
  • Locus provides clients powerful software tools to track and manage various emissions streams.
  • “We are excited that the Port Authority selected Locus Technologies for their ambitious goal of tracking all carbon emissions, including all construction activities.

Clartias Chief AI Officer Rex Briggs to Keynote Possible

Retrieved on: 
Tuesday, April 9, 2024
Progressive Corporation, University, Learning, Integration, Social media, Marketing, Microsoft, Council, IAB, SVP, WIRED, Face, McDonald's, MIT Press, NPR, Ad Council, CMOS, ROI, Digital, Corporation, Internet, CNBC, AI, Ad Age, Book, Daniel Yankelovich, ANA, Digital marketing, Algorithm, MIT, Software, CNN, CAP, Bloomberg, Possibility, Economist, Hall, Interactivity, Management

Cincinnati, Ohio, April 08, 2024 (GLOBE NEWSWIRE) -- Claritas ®, a data-driven marketing leader that leverages a proprietary identity graph to help marketers achieve superior ROI, today announced that its Chief AI Officer Rex Briggs will deliver a keynote discussion at Possible 2024.

Key Points: 
  • Cincinnati, Ohio, April 08, 2024 (GLOBE NEWSWIRE) -- Claritas ®, a data-driven marketing leader that leverages a proprietary identity graph to help marketers achieve superior ROI, today announced that its Chief AI Officer Rex Briggs will deliver a keynote discussion at Possible 2024.
  • In addition to Briggs, other speakers at Possible 2024 include: Linda Boff, GE Chief Marketing Officer VP, Learning & Culture President, GE Foundation; Esi Eggleston Bracey, Chief Growth & Marketing Officer, Unilever; Tariq Hassan, Chief Marketing & Customer Experience Officer, McDonald's Corporation; Diana Haussling, SVP - GM Consumer Experience and Growth, Colgate-Palmolive;  Linda Lee, Chief Marketing Officer, Campbell’s Soup; Frank Cooper III, Chief Marketing Officer, Visa;  Remi Kent, Chief Marketing Officer, Progressive Insurance; David Droga, Chief Executive Officer, Accenture Song; Soyoung Kang, Chief Marketing Officer, Eos; Dana Marineau, Chief Marketing Officer, Rakuten; Bozoma Saint John, Hall of Fame Inducted Marketing Executive, Author, and Entrepreneur; Jaime Teevan, Chief Scientist, Microsoft and Gary Vaynerchuk, Chairman, VaynerX.
  • During Briggs’ work with the Ad Council, he discovered ArtsAI and experimented with its patented AI Personalization technology.
  • In his latest book, “The AI Conundrum” (MIT Press), Briggs and co-author Caleb Briggs explore why artificial intelligence’s strengths are also AI’s weaknesses – and how businesses can effectively apply AI to improve their business.

Nucleai and GoPath Diagnostics Announce Strategic Collaboration to Provide Integrated AI-powered Digital Pathology Solutions for Clinical Research and Diagnostic Applications

Retrieved on: 
Monday, April 8, 2024
Other Health, Software, Research, Pharmaceutical, Oncology, Technology, Artificial Intelligence, Genetics, Health Technology, Science, Biotechnology, Health, College, GCP, LMS, Algorithm, Prostate cancer, Case management, Good clinical laboratory practice, Partnership, LIMS, CLEP, Biomarker, GCLP, AI, CAP, Good clinical practice, IBD, Medicine, Workflow, CLIA, Pathology, Inflammatory bowel disease, Medical director, Medical device

Nucleai , a spatial AI biomarker company that deciphers cellular conversations and maps cellular interactions within tissue samples to predict therapeutic outcomes, today announced a strategic collaboration with GoPath Diagnostics , a leading full-service digital pathology and molecular diagnostics laboratory.

Key Points: 
  • Nucleai , a spatial AI biomarker company that deciphers cellular conversations and maps cellular interactions within tissue samples to predict therapeutic outcomes, today announced a strategic collaboration with GoPath Diagnostics , a leading full-service digital pathology and molecular diagnostics laboratory.
  • This partnership unites Nucleai and GoPath's complementary skills to expedite the development of new AI-powered clinical research and diagnostics.
  • The integrated solutions will be deployed within a centralized environment that meets the standards of the College of American Pathologists (CAP), Clinical Laboratory Improvement Amendments (CLIA), Clinical Laboratory Evaluation Program (CLEP), Good Clinical Practice (GCP), and Good Clinical Laboratory Practice (GCLP).
  • Jim Lu, M.D., CEO and Medical Director for GoPath Diagnostics, said: “Our collaboration with Nucleai transforms our capabilities, enabling GoPath to deliver a seamlessly integrated lab workflow.

bioAffinity Technologies Reports Fourth Quarter and Full Year 2023 Financial Results

Retrieved on: 
Monday, April 1, 2024
Medical Devices, Surgery, FDA, Genetics, Clinical Trials, Biotechnology, Radiology, Pharmaceutical, Health, Oncology, Research, Lung cancer, Growth, CFO, Laboratory developed test, Form, Patient, Accounting, Bronchoalveolar lavage, Sale, Acquisition, Cancer, CPA, CAP, Insurance, MBA, Lung, BAL, BIAF, Bronchoscopy, LDT, Optimism, Medicare, Calendar, Marketing, CMS, Physician, Pharmaceutical industry

Revenue for the fourth quarter of 2023 was approximately $2.2 million, up from no revenue for the prior-year period.

Key Points: 
  • Revenue for the fourth quarter of 2023 was approximately $2.2 million, up from no revenue for the prior-year period.
  • Research and development expenses were $432,000 for the fourth quarter of 2023, compared with $429,000 for the comparable period in 2022.
  • Selling, general and administrative expenses were $2.2 million for the fourth quarter of 2023, compared with $1.2 million for the comparable period in 2022.
  • Net loss for the fourth quarter of 2023 was $2.4 million, compared with a net loss of $1.7 million for the comparable period in 2022.

Nucleus Genomics launches to bring whole-genome sequencing to the public

Retrieved on: 
Monday, March 25, 2024
Technology, Research, Medical Devices, Genetics, Biotechnology, Health, Pharmaceutical, Science, Consumer Electronics, Human Genome Project, WGS, Blood pressure, Genomics, Certification, Informatics, Genetic testing, Nucleus, Risk, Human, PRS, DNA, Accreditation, Breast, CAP, Overalls, Facial muscles, Cancer, CLIA, Breast cancer, BRCA2, BMI, BRCA1, Vaccine

Nucleus Genomics , the next-generation genetic testing and analysis company, today announced the launch of its DNA analysis product to bring the benefits of personalized medicine to everyone.

Key Points: 
  • Nucleus Genomics , the next-generation genetic testing and analysis company, today announced the launch of its DNA analysis product to bring the benefits of personalized medicine to everyone.
  • Nucleus will also offer pre-orders for its premium clinical-grade whole-genome sequencing (WGS) service, in which a customer’s entire set of DNA will be read and analyzed.
  • Nucleus is proud to sequence all customer samples in the U.S. on Illumina’s NovaSeq X Plus, the sequencing company’s newest and most innovative high-throughput sequencing instrument.
  • Working with Illumina, Nucleus is leveraging this latest sequencing technology to make WGS broadly accessible to power personalized healthcare.

Spectrum Solutions® Releases the New SimplyPERIO™ Saliva Test Powered by SimplyTest®

Retrieved on: 
Thursday, March 21, 2024
Medical Devices, Hospitals, Dental, Health Technology, Practice Management, Biotechnology, Other Health, Health, General Health, Temperature, Radioactive decay, Science, USPS, Infection, Disease, Fungus, Peri-implantitis, Central nervous system, Inflammation, Third party, CAP, Patient, Doctor of Philosophy, Artery, Periodontal disease, Saliva, Immunity, Mouth, Heart, Gingivitis, Collection, Dentistry

Spectrum Solutions ®, saliva diagnostic biotech leader, today announced the official release of a new saliva diagnostic testing innovation, SimplyPERIO™.

Key Points: 
  • Spectrum Solutions ®, saliva diagnostic biotech leader, today announced the official release of a new saliva diagnostic testing innovation, SimplyPERIO™.
  • In addition, gum disease decreases a person’s ability to fight infection and inflammation.
  • SimplyPERIO™ uses a proprietary molecular technology to test for and measure periodontal bacteria, caries, fungal and viral targets all for one affordable cost.
  • “We are using science to make saliva diagnostics simple for both Patients and Providers.

Inocras Inc. Unveils Rebranding of Genome Insight

Retrieved on: 
Monday, March 18, 2024
Technology, Neurology, Genetics, Biotechnology, Other Health, Health, Data Management, Artificial Intelligence, Oncology, Disease, Patient, Research, Cancer, AI, CAP, CLIA, Whole genome sequencing, Nursing care plan, Antibiotics

Inocras, formerly known as Genome Insight, announced today its rebranding initiative to reflect its commitment to innovation and user-centric healthcare solutions.

Key Points: 
  • Inocras, formerly known as Genome Insight, announced today its rebranding initiative to reflect its commitment to innovation and user-centric healthcare solutions.
  • The AI-driven whole genome platform company, specialized in whole genome sequencing and analytics for cancer and rare diseases, has embarked on its rebranding to reinforce its dedication to shaping an "innovative tomorrow".
  • The rebranding accentuates its focus on "user-centric approaches" for patients, providers, and researchers, surpassing the provision of sequencing and analytics services.
  • Inocras Inc. (formerly Genome Insight Inc.) is a pioneering provider of whole genome sequencing and analytics services for cancer and rare diseases.

Genseq Selects Sapio LIMS to Power Best-in-Class Next-Generation Sequencing Services

Retrieved on: 
Monday, March 18, 2024
Software, Research, Professional Services, Pharmaceutical, Data Management, Apps, Applications, Technology, Health Technology, Data Analytics, Science, Biotechnology, Health, Other Science, Quality control, Genomics, Laboratory information management system, Communication, LIMS, NGS, AI, CAP, ELN, Al Ain Oasis, GxP, Fine chemical

Founded in 2023, Genseq uses state-of-the-art sequencing platforms, including Novaseq, Nextseq, and Nextseq Dx, to ensure excellent quality and accuracy in sequencing data generation.

Key Points: 
  • Founded in 2023, Genseq uses state-of-the-art sequencing platforms, including Novaseq, Nextseq, and Nextseq Dx, to ensure excellent quality and accuracy in sequencing data generation.
  • In addition to providing a full range of genomics, transcriptomics, and single-cell sequencing services, Genseq’s biobanking facility can accommodate more than 500,000 samples.
  • Genseq will use the advanced LIMS functionality from Sapio to track all aspects of sample management , including sample accessioning, storage, quality control, and aliquoting.
  • “Sapio is supporting Genseq in meeting its promise to clients, and we’re excited to partner with them as they grow their capabilities to meet demand.”

Charles River and Navega Therapeutics Announce Comprehensive Gene Therapy Manufacturing Collaboration

Retrieved on: 
Thursday, March 14, 2024
Research, Medical Devices, Genetics, Clinical Trials, Biotechnology, Health, Pharmaceutical, General Health, Science, Erythromelalgia, AAV, Diabetic neuropathy, CDMO, Patient, CRL, Good manufacturing practice, Gene, DNA, CAP, Chronic pain, Doctor of Philosophy, GMP, Navega, Therapy, Peripheral neuropathy, CGT, Pharmaceutical industry

Charles River Laboratories International, Inc. (NYSE: CRL) and Navega Therapeutics , Inc., a biotechnology company developing epigenetic gene therapies, today announced an AAV9 production program agreement.

Key Points: 
  • Charles River Laboratories International, Inc. (NYSE: CRL) and Navega Therapeutics , Inc., a biotechnology company developing epigenetic gene therapies, today announced an AAV9 production program agreement.
  • As part of Charles River’s Cell and Gene Therapy (CGT) Accelerator Program (CAP), Navega will have access to established contract development and manufacturing (CDMO) capabilities and advisory services to produce an adeno-associated virus (AAV)-based gene therapy, NT-Z001, for Phase I clinical trials.
  • To bring NT-Z001 to clinic, Navega will leverage Charles River’s off-the-shelf plasmid products, custom plasmid capabilities, and Good Manufacturing Practice (GMP)-grade AAV production.
  • Join Ana Moreno, CEO, Navega Therapeutics on March 19 in San Francisco – see the full agenda and save your seat: https://bit.ly/3SW3VOV
    “The collaboration with Navega will tap into our premier gene therapy CDMO capabilities and robust AAV offerings.

Public Comment Period Opens for the “Workup of Amyloidosis” Guideline

Retrieved on: 
Wednesday, March 13, 2024
Education, Managed Care, Health, General Health, Pharmaceutical, Oncology, Other Science, Training, Science, Other Education, Clinical Trials, Amyloid, College, Quality of life, Laboratory, Marie Cassidy, Diagnosis, Patient, Cardiology, Nursing, Disease, CAP, Amyloidosis

—The draft statements are available for public comment through April 3, 2024 on cap.org .

Key Points: 
  • —The draft statements are available for public comment through April 3, 2024 on cap.org .
  • “This process ensures tailored care, early detection, and ongoing optimization of treatment strategies for individuals with amyloidosis,” adds co-chair Billie S. Fyfe-Kirschner, MD, FCAP.
  • Following the open comment period, the guideline authors will consider all feedback to finalize the statements.
  • The final statements will appear in the guideline manuscript and will be available at no cost.